Skip to main content

Table 2 Cytotoxicity in OSCC cells treated with or without metformin and with Cu-GTSM or Cu-ATSM

From: Metformin induces an intracellular reductive state that protects oesophageal squamous cell carcinoma cells against cisplatin but not copper-bis(thiosemicarbazones)

Compounds

LD50(μM)

WHCO1

WHCO5

SNO

Cu-GTSM

1.14 ± 0.16

5.39 ± 0.9

3.37 ± 0.23

Metformin + Cu-GTSM

1.16 ± 0.12

6.24 ± 0.01

4.23 ± 0.7

GTSM

>200

>200

>200

Metformin + GTSM

>200

>200

>200

Cu-ATSM

11.93 ± 0.47

13.51 ± 0.81

7.099 ± 0.57

Metformin + Cu-ATSM

12.54 ± 0.19

12.05 ± 0.83

10.90 ± 0.77

ATSM

>200

>200

>200

Metformin + ATSM

>200

>200

>200

  1. OSCC cells were treated with 10 mM metformin and either GTSM, Cu-GTSM, ATSM or Cu-ATSM and the MTT assay performed. LD50 (μM) was calculated on replicates (n = 3, mean ± SD).